How Does Methylene Blue Both Cure and Cause Methaemoglobinaemia?

Methylene blue can both cure and cause methaemoglobinaemia

Methylene blue is a synthetic, blue dye that also has medicinal uses. Although this drug has become increasingly popular in recent times, not all of the purported uses have strong scientific backing and, to date, methylene blue is approved only for the use of treating methaemoglobinaemia. Interestingly, methylene blue can also cause methaemoglobinaemia. This article will cover the mechanism of action of methylene blue, what methaemoglobinemia is and how methylene blue can also cause the condition it is used to treat.

History and Current Uses

Methylene blue was originally synthesised as a dye for cotton in 1876. It was only years later that its use expanded to biological staining and medicinal applications.

After discovering that the dye would preferentially stain Plasmodium parasites in malaria patients’ blood samples, it was tested as an antimalarial drug, with success. It has now been found that this activity is due to methylene blue’s ability to disrupt the lifecycle of the parasite at various stages.1

To this day, methylene blue is still used as a dye, particularly in medicine as a stain to highlight anatomical structures during surgery, in the lab to stain cells before observation under a microscope or to stain DNA in gel electrophoresis, and as a treatment for fungal and parasitic infections in aquaculture.

Research over the past few years suggests that methylene blue could have uses that extend beyond its current applications.

Recent Research

Methylene blue has been used, with some success, to:

  • Improve the recovery of patients with sepsis or septic shock2
  • Reduce the size of or slow the growth rate of tumours3,4
  • Inhibit or inactivate viruses5,6
  • Kill antibiotic-resistant bacteria7
  • Treat fungal infections8,9
  • Slow the progression of neurodegeneration10

These tests, although preliminary, demonstrate the medicinal potential of methylene blue and closely related compounds. It is currently being further investigated in clinical trials for several of these applications.

Methylene blue treats methaemoglobinaemia through one specific mechanism. This compound, given its ability to treat a broad range of ailments, does not work by this one mechanism alone. We will briefly cover some of these mechanisms further on, but in this article, we will focus on methylene blue’s ability to treat, or cause, methaemoglobinaemia.

Before examining how methylene blue works to treat methaemoglobinaemia, we should first understand what this condition is and how it is typically caused.

Methaemoglobinaemia

Methaemoglobinaemia is a blood disorder characterised by an abnormally high amount of methaemoglobin in the blood. Haemoglobin carries a ferrous (Fe2+) ion which binds to oxygen and delivers it to tissues, but in methaemoglobinaemia, this ferrous ion has been converted to its ferric (Fe3+) state, which is no longer able to bind to oxygen. This disorder can therefore lead to functional anaemia and leave tissues starved of oxygen. It is potentially deadly.

Methaemoglobinaemia can be caused by several factors, including:

  • NADH cytochrome b5 reductase deficiency: This enzyme is responsible for converting Fe3+ to Fe2+, as such, a deficiency can lead to an excess of Fe3+.
  • Structural variants in haemoglobin: This can cause the haeme iron to auto-oxidise from Fe2+ to Fe3+.11
  • Acquired methaemoglobinaemia: Oxidising drugs or toxins can drive the oxidation of Fe2+ to Fe3+. There are a wide variety of compounds that can do this, including anaesthetics such as lidocaine and benzocaine, antimicrobials such as sulphonamides and chloroquine, nitrites such as nitroglycerin and nitric oxide and numerous other medications. These are typically not prescribed in doses high enough to cause methaemoglobinaemia, but there have been circumstances where a standard dose of a prescribed drug has caused this condition.12

Methylene blue can be used as part of a treatment for each of these types of methaemoglobinaemia, when used appropriately. If given in excess, we know that it can also cause acquired methaemoglobinaemia. To better understand why this is, we must understand how methylene blue exerts its activity.

Mechanism of Action

Methylene blue works by several mechanisms. It:

  • Acts as an alternative electron carrier in the electron transport chain, reducing oxidative stress by cycling electrons in the mitochondria and thereby improving mitochondrial function.13
  • Acts as an electron donor to convert Fe3+ into Fe2+. It is first reduced to leukomethylene blue by NADPH-dependent methaemoglobin reductase. Leukomethylene blue can then transfer an electron to Fe3+, converting it to the active Fe2+ and reverting to methylene blue.14
  • Inhibits nitric oxide synthase (NOS) and monoamine oxidase (MAO), which can help to reduce inflammation and pain and offer neuroprotective effects.15,16

It is methylene blue’s ability to be converted to leukomethylene blue and act as a reducing agent that makes it such an effective treatment for methaemoglobinaemia. Now that we know how methylene blue treats methaemoglobinaemia, we will look at how this cure can become the cause.

How Methylene Blue Causes Methaemoglobinaemia

Methylene blue, in lower concentrations, is converted to leukomethylene blue, which acts as a reducing agent. But if a high enough dose of methylene blue is administered, some of it is unable to be metabolised into leukomethylene blue and is left in circulation as methylene blue. This unmetabolised dye acts as an oxidising agent and will oxidise Fe2+ into Fe3+, causing methaemoglobinaemia.

A Glucose-6-phosphate dehydrogenase (G6PD) deficiency can exacerbate this problem, as this enzyme is responsible for converting NADP+ to NADPH. Without sufficient NADPH, methylene blue cannot be converted to leukomethylene blue at a sufficient rate to prevent saturation of the reduction pathway. Methylene blue can accumulate in G6PD deficient red blood cells, causing oxidative damage that may result in red blood cell lysis and haemolytic anaemia. This enzyme deficiency can therefore make a person more susceptible to developing methaemoglobinaemia and haemolytic anaemia as a result of taking methylene blue.

Other factors, such as renal or hepatic impairment, can also lead to prolonged exposure to the dye, increasing the risk of adverse events.17

So how is the risk of developing methaemoglobinaemia reduced when methylene blue must be administered as a treatment?

Mitigating Risk of Developing Methaemoglobinaemia Upon Methylene Blue Treatment

Typically, repeated and high doses exceeding 7 mg/kg can worsen methaemoglobinaemia,18 while doses of 15 mg/kg can directly cause lysis of red blood cells.19 Administering lower doses over longer periods of time can reduce the risk of developing methaemoglobinaemia. Interestingly, methylene blue therapy can result in increased methaemoglobin levels due to a reversal of the reduction reaction after completion of the treatment.11

Conclusion

Methylene blue is a valuable tool in the treatment of methaemoglobinaemia and has shown some exciting results in other areas of medicine. It is readily available to purchase without regulation, as such, people must be aware of not only what its established uses are and how these compare to the more experimental, albeit more exciting, research, but more importantly, how the dose can turn a relatively safe drug into something far more dangerous.

References

  1. Saison N, Franetich JF, Pinilla YT, et al. Rapid and Specific Action of Methylene Blue against Plasmodium Transmission Stages. Pharmaceutics. 2022;14(12):2794. doi:10.3390/pharmaceutics14122794
  2. Ballarin RS, Lazzarin T, Zornoff L, et al. Methylene blue in sepsis and septic shock: a systematic review and meta-analysis. Front Med. 2024;11:1366062. doi:10.3389/fmed.2024.1366062
  3. Pominova DV, Ryabova AV, Skobeltsin AS, Markova IV, Romanishkin ID. Spectroscopic Study of Methylene Blue Interaction with Coenzymes and Its Effect on Tumor Metabolism. Sovrem Tehnol V Med. 2025;17(1):18. doi:10.17691/stm2025.17.1.02
  4. Taldaev A, Terekhov R, Nikitin I, et al. Methylene blue in anticancer photodynamic therapy: systematic review of preclinical studies. Front Pharmacol. 2023;14. doi:10.3389/fphar.2023.1264961
  5. Bojadzic D, Alcazar O, Buchwald P. Methylene Blue Inhibits the SARS-CoV-2 Spike–ACE2 Protein-Protein Interaction–a Mechanism that can Contribute to its Antiviral Activity Against COVID-19. Front Pharmacol. 2021;11:600372. doi:10.3389/fphar.2020.600372
  6. Mohr H, Bachmann B, Klein-Struckmeier A, Lambrecht B. Virus inactivation of blood products by phenothiazine dyes and light. Photochem Photobiol. 1997;65(3):441-445. doi:10.1111/j.1751-1097.1997.tb08586.x
  7. Gazel D, Erinmez M, Çalışkantürk G, Saadat KASM. In Vitro and Ex Vivo Investigation of the Antibacterial Effects of Methylene Blue against Methicillin-Resistant Staphylococcus aureus. Pharmaceuticals. 2024;17(2):241. doi:10.3390/ph17020241
  8. Gómez C, Schuele G, Alberdi E. Medium-term antifungal effects of methylene blue versus flavin mononucleotide in the treatment of moderate toenail onychomycosis. Mycoses. 2024;67(1):e13661. doi:10.1111/myc.13661
  9. Zhang X, Peng G, Pan K, et al. Methylene blue-photodynamic therapy for Microsporum canis infection: investigating a dual mechanism of fungicidal action and neutrophil homeostasis restoration. Front Microbiol. 16:1668703. doi:10.3389/fmicb.2025.1668703
  10. Wischik CM, Stefanacci R, Bentham P, et al. Clinical, imaging and blood biomarker outcomes in a Phase 3 clinical trial of tau aggregation inhibitor hydromethylthionine mesylate in mild cognitive impairment and mild to moderate dementia due to Alzheimer’s disease. J Prev Alzheimers Dis. 2026;13(3):100480. doi:10.1016/j.tjpad.2026.100480
  11. Iolascon A, Bianchi P, Andolfo I, et al. Recommendations for diagnosis and treatment of methemoglobinemia. Am J Hematol. 2021;96(12):1666-1678. doi:10.1002/ajh.26340
  12. Belzer A, Krasowski MD. Causes of acquired methemoglobinemia – A retrospective study at a large academic hospital. Toxicol Rep. 2024;12:331-337. doi:10.1016/j.toxrep.2024.03.004
  13. Yang SH, Li W, Sumien N, Forster M, Simpkins JW, Liu R. Alternative Mitochondrial Electron Transfer for the Treatment of Neurodegenerative Diseases and Cancers: Methylene Blue Connects the Dots. Prog Neurobiol. 2017;157:273-291. doi:10.1016/j.pneurobio.2015.10.005
  14. David SR, Sawal NS, Hamzah MNSB, Rajabalaya R. The Blood Blues: A Review on Methemoglobinemia. J Pharmacol Pharmacother. 2018;9(1):1-5. doi:10.4103/jpp.JPP_79_17
  15. Gureev AP, Sadovnikova IS, Popov VN. Molecular Mechanisms of the Neuroprotective Effect of Methylene Blue. Biochem Biokhimiia. 2022;87(9):940-956. doi:10.1134/S0006297922090073
  16. Lee SW, Han HC. Methylene Blue Application to Lessen Pain: Its Analgesic Effect and Mechanism. Front Neurosci. 2021;15. doi:10.3389/fnins.2021.663650
  17. (PDF) Methylene blue in the intensive care unit: A comprehensive review article. ResearchGate. Published online October 20, 2026. doi:10.35975/apic.v29i4.2829
  18. Lee KW, Lee JB. Antidote for acquired methemoglobinemia: methylene blue. J Korean Med Assoc. 2013;56(12):1084. doi:10.5124/jkma.2013.56.12.1084
  19. Cefalu JN, Joshi TV, Spalitta MJ, et al. Methemoglobinemia in the Operating Room and Intensive Care Unit: Early Recognition, Pathophysiology, and Management. Adv Ther. 2020;37(5):1714-1723. doi:10.1007/s12325-020-01282-5